A study to find out how safe is it to give people a new medicine called “GDC-8264” – including the effect of food on GDC-8264, and the effect of combining GDC-8264 with other medicines

  • Inflammatory Bowel Disease (IBD)
Trial Status:

Completed

This trial runs in
Cities
  • Groningen
Trial Identifier:

GP41678

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This clinical trial was done to study a new medicine called, “GDC-8264”, for the treatment of patients with “inflammatory bowel disease” or “IBD”. This study was done to find out how safe was it for healthy people to get GDC-8264, and how well GDC-8264 was tolerated. Investigators also wanted to find out the effect of food on GDC-8264, and the effect of GDC-8264 on other medicines (drug-drug interaction). Sixty-eight healthy people took part in this study at one study center in one country.

      F. Hoffmann-La Roche Ltd (Switzerland), Genentech Inc (USA) Sponsor
      Phase 1 Phase
      GP41678 Trial Identifier
      All Gender
      18 to 55 Years Age
      Yes Healthy Volunteers

      Healthy volunteers for single ascending dose (SAD; n=38), multiple ascending dose (MAD; n=15), and drug-drug interaction (DDI; n=15) cohorts were enrolled at one study site in the Netherlands to evaluate the safety and tolerability of GDC-8264, with potential activity in patients with inflammatory bowel disease (IBD). All 68 healthy volunteers completed the study and comprised the safety-evaluable population. Results showed single and multiple doses of GDC-8264 taken by mouth were safe and well-tolerated. GDC-8264 can be taken with or without food. One type of measurement indicated DDI, while other measurements did not. There were no deaths or serious adverse events. 

      Trial Summary

      This clinical trial was done to study a new medicine called, “GDC-8264”, for the treatment of patients with “inflammatory bowel disease” or “IBD”. This study was done to find out how safe was it for healthy people to get GDC-8264, and how well GDC-8264 was tolerated. Investigators also wanted to find out the effect of food on GDC-8264, and the effect of GDC-8264 on other medicines (drug-drug interaction). Sixty-eight healthy people took part in this study at one study center in one country.

      F. Hoffmann-La Roche Ltd (Switzerland), Genentech Inc (USA) Sponsor
      Phase 1 Phase
      GP41678 Trial Identifier
      GDC-8264 Treatments
      Inflammatory Bowel Disease Condition
      Official Title

      A phase I, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of oral GDC-8264 and the effect of food on the pharmacokinetics of GDC-8264 in healthy volunteers

      Eligibility Criteria

      All Gender
      18 to 55 Years Age
      Yes Healthy Volunteers

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now